Fatty Liver Disease Collaborative Research in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multi-center, prospective cohort study on the natural history of fatty liver disease in China

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NCT07241195

NAFLD and NASH NAFLD( Non-alcoholic Fatty Liver Disease ) NAFLD Cirrhosis

NOT_YET_RECRUITING

Clinical Characteristics of Metabolic Associated Fatty Liver Disease

NCT06325254

Metabolic Associated Fatty Liver Disease Clinical Features

RECRUITING

Metabolic Subtypes of Non-Alcoholic Fatty Liver Disease

NCT05560997

Non-Alcoholic Fatty Liver Disease Machine Learning

UNKNOWN

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

NCT05421572

Fatty Liver Disease

UNKNOWN

Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences

NCT06908122

Non-alcoholic Fatty Liver Disease

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients with liver biopsy-proven macrovesicular steatosis (\>5%) will be enrolled in the baseline cross-sectional analysis. Those who are either diagnosed as NAFLD or ALD, if meeting all the inclusion and exclusion criteria, will be enrolled in the following cohort study, will be followed up after 1 year, 3 years and 5 years with a visit window of +1 month.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatty Liver Fatty Liver, Alcoholic Non-alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically diagnosed fatty liver disease, confirmed by liver biopsy.
* Specific biopsy requirements: qualified biopsy specimen within 6 months, \>5% hepatocytes show macrovesicular steatosis under HE staining and X10 microscope.
* Only patients with NAFLD or ALD are eligible for the 5-year follow-up cohort study.
* Willing to participate in the long-term follow-up and cooperative.
* Able to provide informed consent file.

Exclusion Criteria

* Unable to provide informed consent.
* Patients are eligible for baseline cross-sectional analysis but not eligible for the cohort section, if having any of the following condition:

1. Any end-stage liver disease.
2. Any malignant tumor.
3. Any infection of hepatitis virus or HIV.
4. Any congenital liver disease such as Wilson disease.
5. Any other serious disease of projected survival \< 5 years.
6. Combined NAFLD and ALD.

Eligible Sex

ALL

Accepts Healthy Volunteers

No